Acurx Pharmaceuticals (ACXP) EBT (2024 - 2026)
Acurx Pharmaceuticals' (ACXP) quarterly EBT came in at -$1.7 million in Q1 2026, up 21.79% YoY from -$1.4 million in Q1 2025, and down 6.51% on a QoQ basis from -$1.6 million in Q4 2025.
Acurx Pharmaceuticals (ACXP) EBT (2024 - 2026) Analysis & Trends
Acurx Pharmaceuticals (ACXP) has 3 years of EBT data on file, last reported at -$1.7 million in Q1 2026.
- Quarterly EBT rose 21.79% year-over-year to -$1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.5 million (up 37.66% YoY) and the FY2025 annual result came in at -$8.0 million, up 44.12% from the prior year.
- EBT slipped to -$1.7 million in Q1 2026, from -$1.6 million in the prior quarter.
- In the past five years, EBT ranged from a high of -$1.6 million in Q4 2025 to a low of -$4.1 million in Q2 2024.
- A 3-year average of -$2.4 million and a median of -$2.2 million in 2025 frame the typical range for EBT.
- Annual changes were most pronounced in 2025 — EBT soared 46.25% — and 2026, when it increased 21.79%.
- Tracing ACXP's EBT over 3 years: stood at -$2.9 million in 2024, then surged by 46.25% to -$1.6 million in 2025, then slipped by 6.51% to -$1.7 million in 2026.
- The last three EBT figures came in at -$1.7 million (Q1 2026), -$1.6 million (Q4 2025), and -$2.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 177.81 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -264.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -11.37 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Acurx Pharmaceuticals | 6.38 Mn | 6.38 Mn | - | -2.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.25 Mn |
| Mar 31, 2026 | -1.68 Mn |
| Dec 31, 2025 | -1.58 Mn |
| Sep 30, 2025 | -1.99 Mn |
| Jun 30, 2025 | -2.25 Mn |
| Mar 31, 2025 | -2.15 Mn |
| Dec 31, 2024 | -2.94 Mn |
| Sep 30, 2024 | -2.82 Mn |
| Jun 30, 2024 | -4.12 Mn |